Severe Combined Immunodeficiency Clinical Trial
Official title:
Induction of Mixed Hematopoietic Chimerism in Patients With Severe Combined Immunodeficiency Disorders Using Allogeneic Bone Marrow and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil
Verified date | July 2019 |
Source | Fred Hutchinson Cancer Research Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot clinical trial studies total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients with severe combined immunodeficiency (SCID) undergoing donor bone marrow transplant. Giving total-body irradiation (TBI) before a donor bone marrow transplant using stem cells that closely match the patient's stem cells, helps stop the growth of abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may mix with the patient's immune cells and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.
Status | Completed |
Enrollment | 6 |
Est. completion date | December 26, 2018 |
Est. primary completion date | October 25, 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients with severe combined immunodeficiency syndrome: - SCID with presence of B lymphocytes - X-linked SCID (presence of B lymphocytes) - Autosomal recessive SCID - Patients with severe combined immunodeficiency syndrome: - SCID with absence of T and B lymphocytes - Patients with severe combined immunodeficiency syndrome: - Purine metabolite deficiencies, deficiencies of the purine metabolites - Adenosine deaminase (ADA) deficiency - Purine nucleoside phosphorylase (PNP) deficiency - DONOR: Related donor who is human leukocyte antigen (HLA) genotypically identical at least at one haplotype and may be genotypically or phenotypically identical for serological typing for HLA-A, B, C, and at the allele level for DRB1 and DQB1; related donors other than siblings must be matched at HLA-A, B, and C (at highest resolution available at the time of donor selection) and at DRB1 and DQB1 by deoxyribonucleic acid (DNA) typing; if more than one HLA-identical sibling is available, priority will be given to the oldest normal donor - DONOR: Unrelated donors who are prospectively matched for HLA-A, B, C, DRB1 and DQB1 by DNA typing at the highest resolution routinely available at the time of donor selection; only a single allele disparity will be allowed for HLA-A, B, or C as defined by high resolution typing Exclusion Criteria: - Patients with viral associated T cell immunodeficiency disorders, such as human immunodeficiency virus (HIV) - Patients with other disease or organ dysfunction that would limit survival to less than 30 days - DONOR: Identical twin - DONOR: Pregnancy - DONOR: HIV seropositive - DONOR: A positive anti-donor cytotoxic cross match is absolute donor exclusion - DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-HLA allele mismatch, i.e., the patient is A*0201, and this type of mismatch is not allowed - DONOR: < 6 months old, > 75 years old |
Country | Name | City | State |
---|---|---|---|
United States | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Fred Hutchinson Cancer Research Center | National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mixed hematopoietic chimerism in a population of pediatric patients with immunodeficiency diseases | It will be established whether a non-lethal conditioning regimen can successfully induce mixed hematopoietic chimerism in a population of pediatric patients with immunodeficiency diseases, without adverse effects on mortality. | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00006335 -
Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID
|
N/A | |
Not yet recruiting |
NCT02231983 -
Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China
|
N/A | |
Active, not recruiting |
NCT03597594 -
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
|
Phase 1/Phase 2 | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Completed |
NCT00001255 -
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study
|
N/A | |
Recruiting |
NCT05651113 -
The Experience of Screening for SCID
|
||
Completed |
NCT00794508 -
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
|
Phase 2 | |
Recruiting |
NCT03538899 -
Autologous Gene Therapy for Artemis-Deficient SCID
|
Phase 1/Phase 2 | |
Recruiting |
NCT05298930 -
Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
Completed |
NCT00845416 -
Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population
|
N/A | |
Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
Completed |
NCT03878069 -
Registry Study of Revcovi Treatment in Patients With ADA-SCID
|
||
Recruiting |
NCT01019876 -
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
|
Phase 2/Phase 3 | |
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02177760 -
Sirolimus Prophylaxis for aGVHD in TME SCID
|
Phase 2 | |
Recruiting |
NCT00695279 -
Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
|
||
Completed |
NCT01420627 -
EZN-2279 in Patients With ADA-SCID
|
Phase 3 | |
Terminated |
NCT02127892 -
SCID Bu/Flu/ATG Study With T Cell Depletion
|
Phase 1/Phase 2 | |
Completed |
NCT04246840 -
Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft
|